Détails du produit
- Genetically modified cell lines best reflect MOA (Mechanism of Action)
- Higher activity and larger assay window for robust and reproducible cell-based bioassay
- Comprehensive application data to support assay development and validation
- Full tracible record, stringent quality control and validated cell passage stability
- Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
- Global commercial license assistance whenever regulatory filing is required
Description
The Raji/Human CD155 Stable Cell Line was engineered to express full length human CD155 (Uniprot: P15151-1), used to mimic cancer target cells. When co-cultured with human TIGIT Reporter Cell, the TIGIT/CD155 interaction inhibits TCR signaling and NFAT-mediated luminescence. Blocking the TIGIT/CD155 interaction by either anti-TIGIT or anti-CD155 antibodies releases the inhibitory signal and results in TCR activation and NFAT-mediated luminescence.
Application
• Useful for cell-based CD155 binding assay
• Useful as CD155-expressing target cells in reporter gene assay

Growth Properties
Suspension
Selection Marker
Hygromycin B (20 μg/mL)
Complete Growth Medium
RPMI-1640 + 10% FBS
Freeze Medium
Serum-free cell cryopreservation medium
Quantity
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
Storage
Frozen in liquid nitrogen.
Mycoplasma Testing
Negative
Sterility Testing
Negative
Instructions for Use
See data sheet for detailed culturing and assay protocol.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
Receptor Assay

Expression analysis of human CD155 on Raji/Human CD155 Stable Cell by FACS.
Raji/Human CD155 Stable Cell Line or negative control cell were stained with PE-labeled anti-Human CD155 antibody.Protocol
Application

Blocking activity of anti-human TIGIT antibody.
This Raji/Human CD155 Stable Cell Line was incubated with serial dilutions of antibodies in the presence of reporter cells expressing human TIGIT. The EC50 of anti-human TIGIT antibody was approximately 2.05 μg/mL.Protocol
Passage Stability

Passage stability analysis of receptors expression by FACS.
Flow cytometry surface staining of human CD155 on Raji/Human CD155 Stable Cell Line demonstrates consistent mean fluorescent intensity across passage 5-28.Protocol
Avis des utilisateurs Publier un commentaire

Déclaration importante
Limited Use&License Disclosure
BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.
- If the researcher is not willing to accept the terms of limited use of this cell line product, and the product is unused, ACRO will accept return of the unused product.
- Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for profit or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research.
- This cell line is neither intended for any animal or human therapeutic purposes nor for any direct human in vivo use. You have no right to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
- ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
- ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
- Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order@acrobiosystems.com for further details.
Progrès de frontière
- Nom anglais:
Poliovirus receptor
- Catégorie:
- Nombre de médicaments répertoriés:
0 Détails
- Nombre de médicaments cliniques:
2 Détails
- Étape de développement la plus élevée:
Phase 2 Clinical




















